trending Market Intelligence /marketintelligence/en/news-insights/trending/aAzpJvn2x3KOesgChhGqrw2 content esgSubNav
In This List

Achillion drug secures second US FDA orphan drug designation

Blog

Insight Weekly: Banks brace for recession; Europe PE deal values soar; US solar imports rebound

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook


Achillion drug secures second US FDA orphan drug designation

Achillion Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's orphan drug designation for ACH-4471 to treat a rare, kidney-related disease known as C3 Glomerulopathy.

ACH-4471 previously received the U.S. FDA's orphan drug designation to treat paroxysmal nocturnal hemoglobinuria that is characterized by red blood cell destruction, blood clots and impaired bone marrow function.